Results: Twenty studies were included. A total of 130 procedures in 120 patients were performed. Ninety percent of included studies concerned case reports or case series. It is described that radioguided surgery with iodinelabeled MIBG can improve the quality of macroscopic resection of neuroendocrine tumors in selected cases, ie, in cases where the tumor is small, nonpalpable, difficult to visualize on conventional imaging studies, or located in an area with adhesional scar tissue from previous surgery. However, in a substantial number of cases the gamma probe failed due to technical problems. Conclusions: Since there is limited evidence that radioguided surgery contributes substantially in resection of neuroendocrine tumors, we cannot advocate its use in general. However, we can conclude that it can seemingly improve the quality of resection in selected cases. When radioguided surgery is performed in neuroendocrine tumors, we advocate the use of 125 I to label MIBG.
BACKGROUND
Neuroendocrine tumors (NETs) are rare, slow-growing tumors characterized by the expression of different peptides and biogenic amines. 1 Although most NETs are asymptomatic in early stages, hypersecretion of these peptides, amines, or their metabolic by-products can cause various clinical symptoms, eg, flushing and secretory diarrhea due to hypersecretion of serotonin. 2, 3 Surgical removal is the treatment of choice to lengthen survival and bring relief from hyperfunctional status. 4 However, NETs may be difficult to localize, especially in the early stages.
Recently, radioguided surgery (RGS) with iodine-labeled metaiodobenzylguanidine was successfully utilized in our center for resection of two 5-mm left para-aortic ganglioneuromas, which, because of their small size, would probably have been difficult to localize otherwise. 5 Metaiodobenzylguanidine (MIBG) is a guanethidine analog, which resembles norepinephrine. Therefore, it is taken up by and stored in sympatho-adrenergic tissue of NETs. 6 MIBG can be labeled with iodine isotopes ( 123 I, 125 I, or 131 I) at the benzoic ring of this tracer. Radioactive MIBG is commonly used in imaging studies to identify NETs. However, it can also be used in radioguided surgery (RGS) of these tumors in which a handheld gamma probe is used to detect in situ tumor binding of radioactive MIBG.
To date, no systematic review has been published giving an overview of the contribution of RGS in resection of NETs. Therefore, the aim of the present systematic review was to assess the role of RGS with iodine-labeled MIBG in resection of neuroendocrine tumors.
MATERIALS AND METHODS

Eligibility Criteria
Original manuscripts describing surgical procedures for (metastatic) NETs in which RGS with iodine-labeled MIBG was used were eligible for inclusion. Comments and editorials were excluded.
Eligible studies were restricted to languages familiar to the authors (English, French, German, and Dutch). Furthermore, in case of multiple studies describing the same cohort of patients, only the study that comprised the highest number of subjects was included for this review.
Search Strategy
In July 2011, PubMed, EMBASE, Web of Science, COCHRANE, CINAHL, Academic Search Premier, ScienceDirect, and Wiley were searched to identify potentially relevant studies (see Table 1 ). References of key articles were assessed for additional relevant articles.
Data Extraction
All studies obtained from the search strategy were entered into reference manager software (Reference Manager version 12) and were screened on title and abstract. Potentially relevant studies were retrieved for detailed assessment.
For all included studies, the following data were extracted: first author and year of publication, type of NET, number of patients studied, contribution of the gamma probe to the surgical procedure, isotope used, site where the NET was localized, and size of the NET.
RESULTS
Search Strategy and Study Selection
The initial search resulted in 133 unique records; 21 were selected for detailed assessment (Fig. 1 ). After detailed assessment, 4 articles were excluded for the following reasons: no original data (n = 1) and cohort of patients already reported in other included studies (n = 3). Three new articles were found in references of key articles, so a total of 20 studies were included in the present review. 7Y26 Of these 20 studies, 14 were written in English, 2 in German, and 4 in French.
(90%) concerned case reports or case series. A total of 130 procedures in 120 patients were performed.
Regarding the type of NET in which RGS with iodine-labeled MIBG was performed, ten studies concerned (metastases of ) pheochromocytomas. 7Y9,12,13,15,19Y21,26 Furthermore, 6 studies concerned ganglioneuromas/(ganglio)neuroblastomas, 10,14,16Y18,25 3 metastases of carcinoid tumors, 11, 22, 24 and 1 a medullary thyroid carcinoma. 23 Concerning type of isotope, 123 I was used in 13 studies, 8,9,14Y16, 19Y26 125 I in 4, 11Y13,17 and 131 I in 1. 7 One study compared 125 I to 123 I in RGS for neuroblastoma. 18 In one study, it was not reported which iodine radionuclide was used. 10 
Role of RGS With Iodine-Labeled MIBG in Resection of NETs
RGS contributed to the surgical decision making in resection of NETs in 93 of 130 procedures (72%). RGS was of use to the surgeon in several ways (see Table 2 ). First, it contributed in localizing the lesion, especially when the lesion was small and therefore not visible or palpable, or when it was embedded in an area with scarring due to previous surgery.
It was also helpful in detecting lesions which were difficult to localize beforehand because of discrepancy between images made by conventional imaging techniques, ie, CT or MRI, and radionuclide imaging techniques, eg, MIBG or somatostatin receptor scintigraphy. Furthermore, using the gamma probe contributed to the detection of lesions which were preoperatively not visualized at all: Proye et al 12 described a case in which the gamma probe identified 2 malignant pheochromocytoma deposits behind the inferior vena cava, which were preoperatively not visualized by 131 I-MIBG scanning.
RGS also proved helpful in defining the extent of tumors and tumor limits. Subsequently, the resected area can be reduced: Spapen et al 9 used the gamma probe to detect a metastasis of a pheochromocytoma as small as 15 mm in the right hilum of the lung, allowing surgery to be limited to a right lower lobectomy. In addition, after excision of the tumor, the gamma probe could be used to check the tumor bed for completeness of resection by the demonstration of counts that were down to normal-tissue levels.
In 7 procedures, it was not reported whether the use of RGS had influenced surgical decision making.
Despite the positive results, some disadvantages in using RGS with iodine-labeled MIBG were reported. In 1 out of 7 surgical procedures for neuroblastoma described by Gruner et al, 10 the gamma probe failed due to technical problems. Technical problems were also an issue in 1 of 19 surgical interventions for neuroblastoma, described by Huglo et al, 17 and in 2 of 66 surgical procedures, also for neuroblastoma, described by Martelli et al. 18 Furthermore, in the latter study, the MIBG uptake was insufficient to provide a positive signal in five cases and in four cases, the shape and diameter of the straight probe prevented detailed exploration of intervertebral foramina or interspaces. At last, several studies report MIBG detection as not contributory in cases where the tumor was large and thus complete removal was easy. 18, 19 
DISCUSSION
The present review aimed to assess the role of RGS with iodinelabeled MIBG in resection of neuroendocrine tumors. The results indicate that RGS with iodine-labeled MIBG may be feasible in the resection of NETs in selected cases. However, the main limitation of this review is that 90% of included manuscripts concerned case reports or case series. This methodological limitation prohibits simple generalization of the results from the perspective of a review since the two larger studies will skew all conclusions. More cohort studies are warranted to further evaluate the role of RGS in NETs.
The included manuscripts used 123 I, 125 I, or 131 I as radionuclides. The study with the 131 I-labeled tracer was published in 1984. 7 131 I was the first radionuclide of iodine used in RGS and the principle gamma photon emission energy principally utilized is that of the 364-keV gamma photon. However, the highly energetic nature of these gamma photons increases background counts, secondary to scatter, and subsequently reduces tumor detection efficiency of the gamma probe. Secondly, the beta particulate emissions of 131 I contribute significantly to the absorbed dose of radiation to the patient and thus limit the amount of activity that can be administered. 27 The principle gamma photon radiation emissions for 123 I are 159 or 529 keV and are therefore characterized as medium-to highenergy emissions, while 125 I has a very low-energy emission of 35 keV. 28 This low gamma photon emission energy, in combination with the high soft tissue attenuation of 125 I, makes this radionuclide advantageous in gamma probe detection of tumor in RGS. 27 This is demonstrated by Martelli et al, 18 who compared the use of 125 I to 123 I to label MIBG in RGS for neuroblastoma. In this study, the sensitivity (positive probe detection/total tumor samples found by the pathologist) was equal for 123 I and 125 I (91% and 92%). However, the specificity (negative probe detection/total tumor-free samples) of 125 I was significantly higher than that of 123 I (85% and 55%). Furthermore, false-positive results were more frequent with 123 I than with 125 I. This can be explained by the short half-life of 123 I, which requires surgery to be performed 24 to 48 hours after injection, when the level of the normal tissue background is still high. As a matter of fact, the depth of the field is increased by the medium-to high-energy emission of 123 I, which enlarges the investigated area, with an uncertain origin of signal. Therefore, using 125 I to label MIBG appears to have several advantages over using 123 I.
Based on our own successful experience with radioguided surgery (RGS) with iodine-labeled MIBG in resection of two small ganglioneuromas, 5 in this review, we sought to assess the role of RGS using radiolabeled MIBG as a tracer. Radiolabeled MIBG was the first radiopharmaceutical used for imaging and therapy of NETs 29 ; however, its sensitivity and specificity vary between different types of NETs. For detection of neuroblastoma and pheochromocytoma, radiolabeled MIBG scintigraphy has a sensitivity and specificity of more than 90%, 30 but in detecting other NETs a sensitivity of only 17Y71% has been reported. 31 Consequently, it seems most feasible to perform RGS using radiolabeled MIBG as a tracer in resection of adrenomedullary tumors.
Other tracers have been used for the detection of NETs. Somatostatin analogs are taken up by NETs expressing somatostatin receptors on their surface, such as gastroenteropancreatic tumors. Therefore, radiolabeled somatostatin analogs, eg, 111 In-pentetreotide, are also routinely used for detecting NETs, although uptake is sometimes also visible in tumors other than NETs, granulomas, and autoimmune disease. 32 111 In-pentetreotide scintigraphy has a higher sensitivity than 123 I-MIBG scintigraphy for detecting metastatic lesions in patients with carcinoid tumors, pancreatic islet cell tumors, and medullary thyroid carcinomas, but a lower sensitivity for detecting malignant pheochromocytomas/paragangliomas. 33 For that reason, it might be feasible to perform RGS with radiolabeled somatostatin analogs instead of radiolabeled MIBG in resection of NETs, other than adrenomedullary tumors. A few cases have already been described in which RGS with radiolabeled octreotide was successfully used for resection of the following NETs: bronchial carcinoids, 34Y36 head-andneck paragangliomas, 37 midgut carcinoids, and an endocrine pancreatic tumor. 38 In recent years, the introduction of imaging techniques combining both anatomic and functional information, ie, positron emission tomography/computed tomography (PET/CT) and single photon emission tomography/computed tomography (SPECT/CT), has led to a vast improvement in the detection of occult cancer and preoperative tumor localization. For PET studies, there are several highly specific radiopharmaceuticals available that reflect different metabolic pathways of NETs, eg, 18 F-fluorodeoxyglucose (FDG) in glucose metabolism, 18 F-fluorodopamine (FDA), and 18 F-3,4-dihydroxy-6fluoro-DL-phenylalanine (DOPA) in the uptake of hormone precursors and 68 Ga-1,4,7,10-tetraazacyclododecane-N,N,N,N-tetraacetic acid (DOTA) D-Phe1-Tyr3-Thr8-octreotide (TATE) in the expression of somatostatin receptors. These new PET radiopharmaceuticals might make MIBG redundant in the future: several studies have reported a superior sensitivity of 18 F-FDG, 18 F-FDA, 18 F-DOPA, and 68 Ga-DOTA-TATE compared to MIBG for the detection of NETs, especially those with a high proliferation index. 31, 39, 40 Although some promising results have been reported concerning radioguided surgery using an intraoperative PET probe for differentiated thyroid cancer, metastatic colon cancer, melanoma, and recurrent ovarian cancer, 41Y44 its role in RGS for NETs has yet to be explored.
CONCLUSIONS
We conclude that data on the use of RGS with iodine-labeled MIBG in resection of neuroendocrine tumors are scarce; therefore, we cannot advocate its use in general. However, in selected cases, RGS with radiolabeled MIBG does seem able to improve quality of resection, ie, in cases where the tumor is small, nonpalpable, difficult to visualize on conventional imaging studies, or located in an area with adhesional scar tissue. RGS using radiolabeled MIBG as tracer seems most feasible in resection of adrenomedullary tumors. We advocate the use of 125 I to label MIBG.
